Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.

BACKGROUND In response to the isolation of the BRCA1 gene, a breast-ovarian cancer-susceptibility gene, biotechnology companies are already marketing genetic tests to health care providers and to the public. Initial studies indicate interest in BRCA1 testing in the general public and in populations at high risk. However, the optimal strategies for educating and counseling individuals have yet to be determined. PURPOSE Our goal was to evaluate the impact of alternate strategies for pretest education and counseling on decision-making regarding BRCA1 testing among women at low to moderate risk who have a family history of breast and/or ovarian cancer. METHODS A randomized trial design was used to evaluate the effects of education only (educational approach) and education plus counseling (counseling approach), as compared with a waiting-list (control) condition (n = 400 for all groups combined). The educational approach reviewed information about personal risk factors, inheritance of cancer susceptibility, the benefits, limitations, and risks of BRCA1 testing, and cancer screening and prevention options. The counseling approach included this information, as well as a personalized discussion of experiences with cancer in the family and the potential psychological and social impact of testing. Data on knowledge of inherited cancer and BRCA1 test characteristics, perceived risk, perceived benefits, limitations and risks of BRCA1 testing, and testing intentions were collected by use of structured telephone interviews at baseline and at 1-month follow-up. Provision of a blood sample for future testing served as a proxy measure of intention to be tested (in the education and counseling arms of the study). The effects of intervention group on study outcomes were evaluated by use of hierarchical linear regression modeling and logistic regression modeling (for the blood sample outcome). All P values are for two-sided tests. RESULTS The educational and counseling approaches both led to significant increases in knowledge, relative to the control condition (P < .001 for both). The counseling approach, but not the educational approach, was superior to the control condition in producing significant increases in perceived limitations and risks of BRCA1 testing (P < .01) and decreases in perceived benefits (P < .05). However, neither approach produced changes in intentions to have BRCA1 testing. Prior to and following both education only and education plus counseling, approximately one half of the participants stated that they intended to be tested; after the session, 52% provided a blood sample. CONCLUSIONS Standard educational approaches may be equally effective as expanded counseling approaches in enhancing knowledge. Since knowledge is a key aspect of medical decision-making, standard education may be adequate in situations where genetic testing must be streamlined. On the other hand, it has been argued that optimal decision-making requires not only knowledge, but also a reasoned evaluation of the positive and negative consequences of alternate decisions. Although the counseling approach is more likely to achieve this goal, it may not diminish interest in testing, even among women at low to moderate risk. Future research should focus on the merits of these alternate approaches for subgroups of individuals with different backgrounds who are being counseled in the variety of settings where BRCA1 testing is likely to be offered.

[1]  C. Isaacs,et al.  Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. , 1997, Patient education and counseling.

[2]  B. Trock,et al.  BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. , 1996, JAMA.

[3]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[4]  N. Nelson Caution guides genetic testing for hereditary cancer genes. , 1996, Journal of the National Cancer Institute.

[5]  Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Swanson,et al.  Recruiting minorities into clinical trials: toward a participant-friendly system. , 1995, Journal of the National Cancer Institute.

[7]  W J Hall,et al.  Women's receptivity to testing for a genetic susceptibility to breast cancer. , 1995, American journal of public health.

[8]  C. Lerman,et al.  Interest in genetic testing among first-degree relatives of breast cancer patients. , 1995, American journal of medical genetics.

[9]  J. Struewing,et al.  Anticipated uptake and impact of genetic testing in hereditary breast and ovarian cancer families. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  M. Skolnick,et al.  A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. , 1995, JAMA.

[11]  B. Rimer,et al.  Effects of individualized breast cancer risk counseling: a randomized trial. , 1995, Journal of the National Cancer Institute.

[12]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[13]  N. Sharpe Informed consent and Huntington disease: a model for communication. , 1994, American journal of medical genetics.

[14]  M. Andrykowski Psychosocial factors in bone marrow transplantation: a review and recommendations for research. , 1994, Bone marrow transplantation.

[15]  M. Daly,et al.  Attitudes about genetic testing for breast-ovarian cancer susceptibility. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. Emanuel,et al.  Four models of the physician-patient relationship. , 1992, JAMA.

[17]  B. Achinstein,et al.  Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. , 2009, Nutrition reviews.

[18]  Sánchez Ga Hispanic Americans. 1. Mexican Hispanics. , 1987 .

[19]  Risk assessment, risk perception and decision making about courses of action involving genetic risk: an overview of concepts and methods. , 1987, Birth defects original article series.

[20]  A. Patenaude,et al.  The physician's influence on informed consent for bone marrow transplantation , 1986, Theoretical medicine.

[21]  Natalie W. Paul,et al.  Birth defects, original article series , 1982 .

[22]  I. Ajzen,et al.  Understanding Attitudes and Predicting Social Behavior , 1980 .

[23]  Ramon J. Aldag,et al.  Decision Making: A Psychological Analysis of Conflict , 1980 .

[24]  Lubs Ml Does genetic counseling influence risk attitudes and decision making , 1979 .

[25]  S. Kessler Genetic counseling : psychological dimensions , 1979 .

[26]  Risk, communication, and decision making in genetic counseling. , 1979, Birth defects original article series.

[27]  F. Fraser,et al.  Genetic counseling: provision and reception of information. , 1979, American journal of medical genetics.

[28]  I. Janis,et al.  Decision Making: A Psychological Analysis of Conflict, Choice, and Commitment , 1977 .

[29]  Powledge Tm Genetic screening as a political and social development. , 1974 .

[30]  T. Powledge Genetic screening as a political and social development. , 1974, Birth defects original article series.

[31]  G A Chase,et al.  Genetic counseling: a consumers' view. , 1972, The New England journal of medicine.